News & events

News & events

Filter by:
  • News

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling...

  • News

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m...

  • News

VarmX raises € 32 million series B financing

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion...
  • News

VarmX raises € 12.5 million to develop VMX-COO1

VarmX, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced...
  • News

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants...
  • Scientific publications

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to...

  • News

VarmX raises seed capital for development of VMX-C001

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis,...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio